Trial Profile

A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

28 Jul 2010 Additional lead investigator (Badiah Yahya, MD) identified as reported by ClinicalTrials.gov.
27 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
27 Jul 2010 Actual initiation date (April 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com